Alexander Aristarkhov is a Director of R&D, Strategic Research, Business, and Investment Consultant with an impressive academic background as Harvard faculty, and a broad experience in developing research, diagnostic platforms, and pharmaceutical modalities. With an analytical mind and an unmatched scientific and technological vision, Alexander generates ideas for new product and services concepts, and manages project and alliances efficiently by providing scientific expertise and business due diligence and implementation. The areas of expertise Alexander has include Research Management, Technology Development, Strategic Initiatives for New Product, Assay Development, Cell Biology, RNA Therapeutics and Diagnostics, Stem Cells and Cell Therapeutics, Extracellular Vesicles, Exosomes, Microbiome, Drug Discovery, Preclinical Development, Biomarkers, Cancer, Strategic Alliances, Due Diligence, and Investment Strategy. Alexander studied at the Russian Academy of Science and Lomonosov Moscow State University, and completed two postdoctoral trainings at Harvard Medical School, and a “Short MBA” at Babson Executive Education at Babson College. Alexander has worked in many organizations, including CSO at ALTACELLS, Biopharma Consultant at RNASolutions, New Technologies Assessment and Development Leader at GE Healthcare, Sr. Director of Technology Development at Advirna, Technology Development Leader at Moderna Therapeutics, Strategic Science and Technology consultant at Merck Group, Director Science &Technology, Head of Applications at Exiqon, Associate Director of Biochemistry and Cell Biology at Agenus, Head of Cell Biology Systems R&D, Advanced Research Technologies Division at Applied Biosystems, and Research Assistant Professor, Instructor in Cell Biology, Dept. of Cell Biology at Harvard Medical School, and Research Fellow, Dept. of Microbiology and Molecular Genetics at Harvard Medical School.